Tianchen Bio-B (01779.HK): Topline data from China Phase II clinical trial of LP-005 for the treatment of PNH

Zhitong Finance APP News, Tianchen Bio-B (01779.HK) announced that the top-line data from the Phase II clinical trial (Phase II clinical trial) of LP-005 (a bispecific antibody fusion protein independently developed by the Group, targeting C5 and C3b complement and used for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)) conducted in China have been read out. These top-line data show that LP-005 has significant efficacy and a favorable safety and tolerability profile.